Atrium Therapeutics, Inc. Common Stock (RNA) support and resistance · rev $22.6M
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
This page maps Atrium Therapeutics, Inc. Common Stock (RNA) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
RNA currently screens at market cap $217.5M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new RNA 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the RNA quote page for the session range and the stock page for the full model.
Not investment advice.